Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
States Continue to Target AI-Driven Rental Pricing Nineteen states are considering bills that would limit the use of third-party software relying on competitor data to set rental housing prices, according...
Trump, Congress Weigh Measures to Preempt State AI Laws The Trump administration circulated—and then put on hold—a draft executive order aimed at preempting state laws regulating artificial...
Last year, after Colorado and California became the first states in the nation to expand privacy protections to include neural data, we said more states could follow suit . This year two more have done...
MI Lawmakers Advance Medical Debt Protections The Michigan Senate’s Health Policy Committee has advanced a trio of bipartisan bills aimed at reducing the burden of medical costs on residents of...
EU Reversing Course on Tech Regulation After aggressively regulating the technology industry for over a decade, the European Union is moving to loosen its landmark digital privacy and artificial intelligence...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
California joined a nationwide movement to tighten restrictions on pharmacy benefit managers with the approval of SB 966 days before adjourning its legislative session on Aug. 31. If signed by Gov. Gavin Newsom (D) the measure will establish licensing requirements for PBMs and require them to report to the state’s Department of Insurance the fees they charge pharmacies and the rebates they receive from drug manufacturers. The bill would also require PBMs to pass along 100% of those rebates to health plans or insurers. (PLURIBUS NEWS, LEXISNEXIS STATE NET)
In 2021, Arkansas became the first state to pass a law requiring pharmaceutical manufacturers that participate in Medicaid to sell drugs to contract pharmacies at a discount under the federal 340B program. Louisiana followed suit in 2023. This year, Kansas (SB 28), Maryland (HB 1056), Mississippi (HB 728), Missouri (SB 751) and West Virginia (SB 325) enacted similar legislation. And other states, including New York (AB 7789), considered similar measures.
The recent legislative actions are pushback against the restriction of 340B drug sales by pharmaceutical companies, which contend the 340B program has expanded beyond its original intent. As of September 2023, 25 drugmakers had done so. (STATELINE)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.